We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effect of Oral Appliance Therapy on Glucose Levels in Patients With T2DM and OSA: A Pilot Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03167684
Recruitment Status : Unknown
Verified September 2017 by Sushmita Pamidi, McGill University Health Centre/Research Institute of the McGill University Health Centre.
Recruitment status was:  Recruiting
First Posted : May 30, 2017
Last Update Posted : September 12, 2017
University of British Columbia
Information provided by (Responsible Party):
Sushmita Pamidi, McGill University Health Centre/Research Institute of the McGill University Health Centre

Brief Summary:
This study will evaluate the impact on blood glucose of the use of an oral appliance to treat obstructive sleep apnea (OSA) in individuals with Type 2 diabetes. An oral appliance is similar to a sports mouth guard or an orthodontic retainer and is an alternative treatment to continuous positive airway pressure (CPAP) for OSA. Oral appliance therapy has not been evaluated in patients with Type 2 diabetes with respect to glycemic outcomes. This will be a 1:1 randomized controlled trial: The experimental group will receive the oral appliance and the control group will receive a sham device over the course of approximately 5 months.

Condition or disease Intervention/treatment Phase
Sleep Apnea, Obstructive Type 2 Diabetes Mellitus Device: Oral appliance therapy Not Applicable

Detailed Description:
OSA is quite common in individuals with T2DM, occurring in as many as 60-80% of patients. The standard treatment for OSA is with the use of a CPAP machine. The CPAP provides an air pressure to keep the airways opened during sleep so that a person with OSA can breathe normally. When used appropriately, the CPAP improves sleepiness and quality of life. However, about half of the patients who receive a CPAP prescription cannot tolerate it and thus remain untreated and are potentially at increased cardiovascular and diabetes risk. In light of this, this study aims to see if the use of an alternative treatment for OSA, oral appliance therapy, where adherence is generally superior to CPAP, will improve cardiometabolic outcomes in individuals with Type 2 diabetes. This pilot trial will primarily examine feasibility and assess recruitment rates.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of Oral Appliance Therapy on Cardiometabolic Outcomes in Patients With Type 2 Diabetes and Obstructive Sleep Apnea: A Pilot RCT
Actual Study Start Date : May 1, 2017
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea

Arm Intervention/treatment
Experimental: Oral appliance therapy
Oral appliance (SomnoMed) worn nightly
Device: Oral appliance therapy
Fitted oral appliance
Other Name: Mandibular advancement device

No Intervention: Control
Sham oral appliance device

Primary Outcome Measures :
  1. Recruitment and retention rates [ Time Frame: End of study (Week 20) ]
    feasibility of study in T2DM

  2. Glycemic control (mean 24-hour and nocturnal glucose) [ Time Frame: End of study (week 20) ]
    24-hour continuous glucose monitoring

Secondary Outcome Measures :
  1. Blood pressure [ Time Frame: End of study (Week 20) ]
    Measurement of clinic blood pressure

  2. Glucose variability [ Time Frame: End of study (Week 20) ]
    Continuous glucose monitoring system (ipro2, Medtronic)

  3. Changes in insulin or diabetes medication doses [ Time Frame: End of study (Week 20) ]
    Reporting of dose change by participant or treating physician.

  4. Systemic inflammation [ Time Frame: End of study (Week 20) ]

Other Outcome Measures:
  1. Oral appliance therapy adherence [ Time Frame: Monitored from Week 0 to week 20 (8 week titration + 12 week treatment) ]
    Measured by a chip embedded in the oral appliance

  2. Subjective sleep quality [ Time Frame: Screening or baseline (Week -4), Week 12 and End of study (Week 20) ]
    Sleep questionnaires

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of T2DM using current Canadian guidelines
  • OSA with AHI > 10 events/hour using current American Academy of Sleep Medicine (AASM) criteria for scoring respiratory events

Exclusion Criteria:

  • On treatment for OSA within the past 3 months
  • Professional drivers or patients with an increased risk of driving-related accidents from clinical interview or severe subjective sleepiness (Epworth sleepiness scale greater than 15)
  • Sleep apnea with any of the following features: highly severe OSA (AHI>50 and oxygen desaturation index > 50), severe hypoxemia (SpO2<80% for >10% of recording time), central sleep apnea or Cheyne-Stokes respirations with a central apnea index >10 events/hour
  • Coexisting sleep disorder other than OSA
  • Active cardiovascular disease, including angina, arrhythmia or congestive heart failure
  • Insufficient dentition or significant periodontal disease or other contraindication for OAT as determined by dentist qualified in OSA treatment
  • Active and significant psychiatric disease
  • BMI>35
  • Regular use of sedatives or narcotics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03167684

Layout table for location contacts
Contact: Sushmita Pamidi, MD MSc 514-934-1934 ext 36479 sushmita.pamidi@mcgill.ca

Layout table for location information
Canada, Quebec
McGill University Health Centre - Research Institute Recruiting
Montreal, Quebec, Canada, H4A2Y3
Contact: Sushmita Pamidi, MD         
Principal Investigator: Sushmita Pamidi, MD         
Sponsors and Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre
University of British Columbia
Layout table for investigator information
Principal Investigator: Sushmita Pamidi, MD MSc Assistant Professor of Medicine
Layout table for additonal information
Responsible Party: Sushmita Pamidi, Clinician Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre
ClinicalTrials.gov Identifier: NCT03167684    
Other Study ID Numbers: 2017-2769
First Posted: May 30, 2017    Key Record Dates
Last Update Posted: September 12, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Towards meta-analysis data

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases